These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19140672)

  • 1. Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS.
    Matsumoto K; Shimizu C; Arao T; Andoh M; Katsumata N; Kohno T; Yonemori K; Koizumi F; Yokote H; Aogi K; Tamura K; Nishio K; Fujiwara Y
    J Proteome Res; 2009 Feb; 8(2):457-62. PubMed ID: 19140672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry.
    Saba JA; Kunkel JP; Jan DC; Ens WE; Standing KG; Butler M; Jamieson JC; Perreault H
    Anal Biochem; 2002 Jun; 305(1):16-31. PubMed ID: 12018942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid quantitative profiling of N-glycan by the glycan-labeling method using 3-aminoquinoline/α-cyano-4-hydroxycinnamic acid.
    Kaneshiro K; Watanabe M; Terasawa K; Uchimura H; Fukuyama Y; Iwamoto S; Sato TA; Shimizu K; Tsujimoto G; Tanaka K
    Anal Chem; 2012 Aug; 84(16):7146-51. PubMed ID: 22830976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid identification of protein biomarkers of Escherichia coli O157:H7 by matrix-assisted laser desorption ionization-time-of-flight-time-of-flight mass spectrometry and top-down proteomics.
    Fagerquist CK; Garbus BR; Miller WG; Williams KE; Yee E; Bates AH; Boyle S; Harden LA; Cooley MB; Mandrell RE
    Anal Chem; 2010 Apr; 82(7):2717-25. PubMed ID: 20232878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.
    Robinson AG; Turbin D; Thomson T; Yorida E; Ellard S; Bajdik C; Huntsman D; Gelmon K
    Clin Breast Cancer; 2006 Aug; 7(3):254-61. PubMed ID: 16942643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural characterization of fucose-containing oligosaccharides by high-performance liquid chromatography and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Suzuki M; Suzuki A
    Biol Chem; 2001 Feb; 382(2):251-7. PubMed ID: 11308023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix-assisted laser desorption/ionization in-source decay combined with tandem time-of-flight mass spectrometry of permethylated oligosaccharides: targeted characterization of specific parts of the glycan structure.
    Wuhrer M; Deelder AM
    Rapid Commun Mass Spectrom; 2006; 20(6):943-51. PubMed ID: 16470682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
    Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical and enzymatic N-glycan release comparison for N-glycan profiling of monoclonal antibodies expressed in plants.
    Triguero A; Cabrera G; Royle L; Harvey DJ; Rudd PM; Dwek RA; Bardor M; Lerouge P; Cremata JA
    Anal Biochem; 2010 May; 400(2):173-83. PubMed ID: 20109437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
    Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
    Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graphene based soft nanoreactors for facile "one-step" glycan enrichment and derivatization for MALDI-TOF-MS analysis.
    Bai H; Pan Y; Tong W; Zhang W; Ren X; Tian F; Peng B; Wang X; Zhang Y; Deng Y; Qin W; Qian X
    Talanta; 2013 Dec; 117():1-7. PubMed ID: 24209301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer.
    Sorensen BS; Mortensen LS; Andersen J; Nexo E
    Anticancer Res; 2010 Jun; 30(6):2463-8. PubMed ID: 20651409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.